171 related articles for article (PubMed ID: 32374627)
1. Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model
Wang M; Zeng Q; Li Y; Imani S; Xie D; Li Y; Han Y; Fan J
J Drug Target; 2020 Nov; 28(9):961-969. PubMed ID: 32374627
[TBL] [Abstract][Full Text] [Related]
2. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy.
Xiang Z; Deng X; He W; Yang Q; Ni L; Dehghan Shasaltaneh M; Maghsoudloo M; Yang G; Wu J; Imani S; Wen Q
Ann Med; 2022 Dec; 54(1):1357-1371. PubMed ID: 35543207
[TBL] [Abstract][Full Text] [Related]
3. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
4. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer.
Yan M; Yang R; Li Q; Wang C; Chen J; Wu Z; Li H; Fan J
Transl Oncol; 2024 Mar; 41():101887. PubMed ID: 38262112
[TBL] [Abstract][Full Text] [Related]
6. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
7. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Zhang K; Wang L; Wei A; Jia X; Liu X
Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
[TBL] [Abstract][Full Text] [Related]
8. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro.
Zhou HJ; Zhang JL; Li A; Wang Z; Lou XE
Cancer Chemother Pharmacol; 2010 May; 66(1):21-9. PubMed ID: 19756601
[TBL] [Abstract][Full Text] [Related]
9. The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.
Liu M; Wang X; Li H; Xu L; Jing L; Jiang P; Liu B; Li Y
Thorac Cancer; 2019 Oct; 10(10):1868-1878. PubMed ID: 31486270
[TBL] [Abstract][Full Text] [Related]
10. Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients.
Liu M; Li H; Wang X; Jing L; Jiang P; Li Y
Cancer Med; 2020 Apr; 9(8):2660-2673. PubMed ID: 32073228
[TBL] [Abstract][Full Text] [Related]
11. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
12. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model.
Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y
Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
14. Ginkgo biloba exocarp extracts inhibits angiogenesis and its effects on Wnt/β-catenin-VEGF signaling pathway in Lewis lung cancer.
Han D; Cao C; Su Y; Wang J; Sun J; Chen H; Xu A
J Ethnopharmacol; 2016 Nov; 192():406-412. PubMed ID: 27649680
[TBL] [Abstract][Full Text] [Related]
15. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.
Fan F; Samuel S; Gaur P; Lu J; Dallas NA; Xia L; Bose D; Ramachandran V; Ellis LM
Br J Cancer; 2011 Apr; 104(8):1270-7. PubMed ID: 21407219
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G;
Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma.
Qin RS; Zhang ZH; Zhu NP; Chen F; Guo Q; Hu HW; Fu SZ; Liu SS; Chen Y; Fan J; Han YW
BMC Cancer; 2018 Oct; 18(1):967. PubMed ID: 30305062
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.
Lin YC; Liu CY; Kannagi R; Yang RB
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1202-1215. PubMed ID: 29545238
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
O'Halloran PJ; Viel T; Murray DW; Wachsmuth L; Schwegmann K; Wagner S; Kopka K; Jarzabek MA; Dicker P; Hermann S; Faber C; Klasen T; Schäfers M; O'Brien D; Prehn JH; Jacobs AH; Byrne AT
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1673-83. PubMed ID: 26975402
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of Xeroderma Pigmentosum Complementation Group C Expression by 17-Allylamino-17-Demethoxygeldanamycin Enhances Bevacizumab-Induced Cytotoxicity in Human Lung Cancer Cells.
Chen JC; Ko JC; Taso YC; Cheng HH; Chen TY; Yen TC; Lin YW
Pharmacology; 2021; 106(3-4):154-168. PubMed ID: 33202406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]